^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Other names: BAY86-5321, AVE0005, AVE-0005, VEGF Trap-Eye, AVE 0005, BAY865321, BAY86 5321
    Company:
    Bayer, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    6d
    A 2-year Study of EYP-1901 in Subjects with Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will Be Determined At Week 52 (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    10d
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    13d
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    18d
    A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO). Primary Efficacy Will be Determined at Week 52. (clinicaltrials.gov)
    P3, N=400, Recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    ASCENT: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (clinicaltrials.gov)
    P3, N=660, Recruiting, AbbVie | N=465 --> 660 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Feb 2025 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    2ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    2ms
    DME HOME: Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT (clinicaltrials.gov)
    P=N/A, N=308, Not yet recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Unity Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    2ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Not yet recruiting, Bayer
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=25, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal) • Fumena (vorolanib)
    2ms
    Comparison of the Efficacy of Conbercept and Aflibercept in Different Treatment Regimens for Exudative Age-related Macular Degeneration (ChiCTR2400087042)
    P4, N=140, Completed, The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    PULSAR: Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (clinicaltrials.gov)
    P3, N=1011, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    3ms
    DAVIO2: Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (clinicaltrials.gov)
    P2, N=160, Completed, EyePoint Pharmaceuticals, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    3ms
    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK (clinicaltrials.gov)
    P3, N=675, Recruiting, Kodiak Sciences Inc
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    3ms
    Tejas: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Ashvattha Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    TELeMAC: Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1 (clinicaltrials.gov)
    P3, N=46, Recruiting, Centre Hospitalier Universitaire Dijon | Trial completion date: Jan 2025 --> Dec 2027 | Trial primary completion date: Jan 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    3ms
    Tejas: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME (clinicaltrials.gov)
    P2, N=50, Recruiting, Ashvattha Therapeutics, Inc. | N=30 --> 50 | Trial completion date: Jun 2023 --> Dec 2024 | Trial primary completion date: May 2023 --> Nov 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    3ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    4ms
    PHOTON: Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (clinicaltrials.gov)
    P2/3, N=660, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    4ms
    Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov)
    P3, N=825, Recruiting, Ocular Therapeutix, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    4ms
    DAZZLE: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (clinicaltrials.gov)
    P2/3, N=559, Terminated, Kodiak Sciences Inc | Phase classification: P2b --> P2/3
    Phase classification
    |
    Eylea (aflibercept intravitreal)
    4ms
    Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov)
    P3, N=825, Not yet recruiting, Ocular Therapeutix, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    4ms
    CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov)
    P1, N=29, Completed, Ocular Therapeutix, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Jan 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    4ms
    ELARA: A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    5ms
    A Study of Longer Interval of IVT IBI302 in Subjects With nAMD (clinicaltrials.gov)
    P2, N=132, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed | Trial primary completion date: Feb 2024 --> May 2024
    Trial completion • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    5ms
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Completed, Regeneron Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    5ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    5ms
    PRECISION: Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=23, Completed, The Cleveland Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT) (clinicaltrials.gov)
    P4, N=23, Completed, Hyewon Chung | Unknown status --> Completed | N=47 --> 23 | Trial completion date: Sep 2022 --> Feb 2024
    Trial completion • Enrollment change • Trial completion date
    |
    Eylea (aflibercept intravitreal)
    6ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Active, not recruiting, Alvotech Swiss AG | Trial completion date: Jan 2025 --> Oct 2024
    Trial completion date
    |
    Eylea (aflibercept intravitreal)
    6ms
    A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy (clinicaltrials.gov)
    P2, N=178, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    6ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=322, Not yet recruiting, Bayer
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    INTRAMED-CRVO: Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion (clinicaltrials.gov)
    P4, N=51, Completed, University of Athens
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E (clinicaltrials.gov)
    P4, N=30, Completed, The University of Hong Kong | Recruiting --> Completed | N=64 --> 30
    Trial completion • Enrollment change
    |
    Eylea (aflibercept intravitreal)
    6ms
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) (clinicaltrials.gov)
    P3, N=35, Active, not recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    7ms
    Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (clinicaltrials.gov)
    P2, N=50, Recruiting, Unity Biotechnology, Inc. | Phase classification: P2b --> P2 | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Mar 2025
    Phase classification • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    7ms
    Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study (clinicaltrials.gov)
    P2, N=30, Completed, Moorfields Eye Hospital NHS Foundation Trust | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    SPECTRUM-US: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=800, Not yet recruiting, Regeneron Pharmaceuticals
    New trial • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    7ms
    VISION-AF: A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (clinicaltrials.gov)
    P4, N=100, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    7ms
    Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Singapore National Eye Centre | Recruiting --> Active, not recruiting | N=160 --> 60
    Enrollment closed • Enrollment change
    |
    Visudyne (verteporfin) • Eylea (aflibercept intravitreal)
    7ms
    One Year Trial Evaluating Safety of Ozurdex With Eylea (clinicaltrials.gov)
    P4, N=50, Completed, Texas Retina Associates | Unknown status --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    8ms
    FIREFLEYE next: Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (clinicaltrials.gov)
    P3, N=96, Active, not recruiting, Bayer | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Jul 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)